<DOC>
	<DOCNO>NCT01760967</DOCNO>
	<brief_summary>Background : Dexmedetomidine , highly selective arfa2-adrenergic agonist , know unique sedative agent cause less acute tolerance , drug addiction withdrawal compare gamma-aminobutyrate ( GABA ) agonists . Dexmedetomidine approve short-term ICU sedation 2004 Japan , use particularly surgical ICU patient . In August 2010 dexmedetomidine approve Japan sedation last 24 hour . Recent evidence demonstrate dexmedetomidine organ protective effect include neuroprotection , cardioprotection , renal protection , gastrointestinal tract action , anti-inflammatory action . Dexmedetomidine show significantly decrease infarct size isolate rat heart . Additionally , dexmedetomidine exhibit precondition effect ischemic injury hippocampal slice , result consider apoptosis suppression effect dexmedetomidine . Aydin C et al report dexmedetomidine enhance spontaneous contraction ileum peritonitis rat compare propofol midazolam . Taniguchi colleague demonstrate dexmedetomidine reduce high mortality rate plasma cytokine concentration , interleukin-6 tumor necrosis factor alpha endotoxemic rat . A meta-analysis show perioperative alfa2-adrenergic agonist , include dexmedetomidine infusion , decrease cardiovascular event patient undergo cardiac surgery . Dexmedetomidine treat patient undergo thoracotomy indicate increase urine output , reduction serum creatinine , suppression diuretic randomize placebo-controlled double-blind study . Septic patient receive dexmedetomidine improve 28-day mortality rate compare septic patient receive lorazepam sub-group analysis MENDS randomize control trial . These positive effect dexmedetomidine cardiovascular system , neuron , kidney , gastrointestinal tract action , anti-inflammatory action , expect improve mortality septic patient . However , large clinical research study conduct yet . We design conduct DESIRE trial ( DExmedetomidine Sepsis ICU Randomized Evaluation trial ) test hypothesis dexmedetomidine may improve clinical outcome organ protective effect septic patient . Objective : To determine whether dexmedetomidine improve clinical outcome organ protective effect septic patient .</brief_summary>
	<brief_title>Dexmedetomidine Sepsis ICU Randomized Evaluation Trial</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>adult transfer ICU anticipation need mechanical ventilation least 24 hour sever chronic liver disease ( Child B C ) acute myocardial infarction , heart disease ( NYHA 4 ) Drug dependence , alcoholism Psychological illness , severe cognitive dysfunction patient allergy dexmedetomidine attend physician 's decision</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Dexmedetomidine</keyword>
	<keyword>sepsis</keyword>
	<keyword>mortality</keyword>
	<keyword>duration mechanical ventilation</keyword>
	<keyword>organ failure</keyword>
</DOC>